Everything below concerns pentapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-19. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Solubility | Freely soluble in water and polar solvents | Dissolution may require brief mixing |
| Typical storage temperature | Minus 20 degrees Celsius or below | Dry, desiccated, protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Purity plus identity confirmation |
| Common synonyms | Ipamorelin acetate, NNC 26-0161 | Research code used in early literature |
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Although there are no official definition to what a member of parliament is, it commonly refers to the elected members of the lower People's Representative Council (Dewan Perwakilan Rakyat, abbr. DPR), known in Indonesian as Anggota DPR (member of the DPR). Members of the upper Regional Representative Council (Dewan Perwakilan Daerah, abbr. DPD) are referred to as senator, although the term Anggota DPD (member of the DPD) is also widely used. These titles are not used in formal naming convention following a member's name unlike the Westminster system. Currently, there are 575 and 136 members in the DPR and the DPD respectively, both elected for a renewable five-year term. Members of the DPR are required to be a member of a registered political party, whereas members of the DPD are independent.
=== Historical === In 1888, the French botanist Gaston Bonnier demonstrated early experimental evidence for lichen symbiosis through his work with X. parietina (then called Parmelia parietina). He reported creating artificial lichen thalli by replacing the organism's natural algal partner (Protococcus viridis) with different algae species, including Protococcus botryoides and the filamentous reddish alga Trentepohlia abietina. While his methods foreshadowed modern microbiological techniques and represented a significant step for the time, modern assessments note critical limitations. His algal sources were not truly isolated (coming from other lichen thalli), and his "synthesized lichens" only vaguely resembled natural specimens, showing fungal hyphae surrounding algal cells but lacking true lichen morphology. In 1967, Richardson conducted early transplant experiments with X. parietina that helped establish methods for studying lichen adaptability. Using a novel technique of attaching lichen thalli to new substrates with resin glue, the study achieved a 96% survival rate in transplanted specimens. When coastal specimens (var. ectanea) were moved to farm roofs in Oxford, they showed significant morphological changes within 18 months, including increased lobe width from 0.8 mm to 2.4 mm. The study also demonstrated that parietin production could adapt to local conditions within six months, with transplanted specimens eventually matching the pigment levels of native populations.
==== Corneal Allogenic Intrastromal Ring Segments (CAIRS) ==== Corneal Allogenic Intrastromal Ring Segment Keratoplasty (CAIRS Keratoplasty) is a modern surgical technique used in the treatment of keratoconus. It involves implanting finely shaped pieces of donor corneal tissue into the corneal stroma to reinforce and reshape the weakened, ectatic cornea, thereby improving both corneal structure and visual clarity. Because CAIRS uses biological graft material and has demonstrated strong outcomes with a favourable safety profile, it is formally recognised as a corneal transplantation procedure by health funding authorities in Australia, the United Kingdom, Japan, Germany, Brazil, the Netherlands, and a number of other countries. In contrast to traditional synthetic intrastromal corneal ring segments (ICRS) made from materials such as PMMA, CAIRS keratoplasty uses preserved allogeneic corneal tissue. This biological compatibility reduces the likelihood of complications sometimes seen with non-organic implants, including extrusion, infection, or chronic foreign body reaction. The CAIRS technique was pioneered by Dr Soosan Jacob, who first introduced it in 2018 through a large case series published in the Journal of Refractive Surgery. One of its key strengths is its suitability for corneas with irregular or decentered cones. The donor segments can be individually designed to achieve targeted corneal flattening and astigmatism improvement.
Sources: en.wikipedia.org
A 2014 Cochrane review found tentative evidence that people treated with sulfonylureas have fewer non-fatal cardiovascular events than those treated with metformin (RR 0.7) but a higher risk of severe hypoglycemia (RR 5.6). There was not enough data available to determine the risk of mortality or of cardiovascular mortality. The FDA requires sulfonylureas to carry a label warning regarding increased risk of cardiovascular death. A 2020 Cochrane systematic review comparing metformin monotherapy to sulfonylureas did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease. Second-generation sulfonylureas have increased potency by weight, compared to first-generation sulfonylureas. Similarly, ACCORD (Action to Control Cardiovascular Risk in Diabetes) and the VADT (Veterans Affairs Diabetes Trial) studies showed no reduction in heart attack or death in patients assigned to tight glucose control with various drugs.
In 2023, Cambrex acquired the Waltham-headquartered chemical process development services provider, Snapdragon Chemistry. In 2024, Cambrex expanded Q1 Scientific with new state-of-the-art, temperature-controlled and monitored, stability storage facility in Durham, North Carolina. In 2025, Cambrex sold its large-scale drug product business unit to Noramco, including its two sites in Whippany, NJ and Mirabel, Quebec.
==== Ovarian function ==== In 2021, a phase I non-randomized clinical trial, the first in humans, evaluated the safety and potential benefits of injecting autologous adipose-derived stem cells (ADSCs) into the ovaries of women with premature ovarian failure (POF). Nine patients received varying doses of ADSCs (5, 10, or 15 million cells), and were followed for up to 12 months. The results showed that there were no serious side effects reported, menstruation resumed in 4 out of 9 patients, serum FSH levels decreased in 4 patients, indicating some hormonal improvement. Additionally, ovarian volume, AMH, and antral follicle count (AFC) showed variable results with no significant differences between groups. The study concluded that intra-ovarian ADSC therapy appears safe and feasible, with some signs of improved ovarian function, though results were inconsistent. Larger randomized trials are needed for confirmation.
Sources: en.wikipedia.org
Reversed-phase liquid chromatography is standard for purity, and mass spectrometry is standard for identity. Amino acid analysis is used when quantitative composition matters. No single technique answers every question, so laboratories usually combine two or three.
The peptide contains aromatic and imidazole groups that absorb ultraviolet light and can participate in photo-induced reactions. Those reactions can alter the molecule or generate new species. Amber glass or opaque packaging reduces the exposure.
Long-term stability data across many temperature and humidity conditions are limited. Most guidance is extrapolated from short studies on related peptides. The effect of repeated handling on a specific lot is generally not characterized.
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.